EMD Serono Research & Development Institute, Inc.
14 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
0
Ending by 2030
Nov 2036
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jul 16, 2027The maintenance fee for Substituted Pyrazoles as Type II Irak Inhibitors (US 11,873,303) comes due Jul 16, 2027. Unpaid by Jan 18, 2028, it lapses early.
Recent changes
- 1 term has ended since Aug 22, 2026
- Sep 13 US 11,440,899 PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF · lapsed on the fee record
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 4 of 4
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,485,786 | Anti-Alpha-V Integrin Antibody for the Treatment of Fibrosis And/Or Fibrotic Disorders In force · Medium confidence | In force | Medium confidence | |
| US 12,054,549 | Anti-Alpha-V Integrin Antibody for the Treatment of Fibrosis And/Or Fibrotic Disorders In force · Medium confidence | In force | Medium confidence | |
| US 11,873,303 | Substituted Pyrazoles as Type II Irak Inhibitors In force · High confidence | In force | High confidence | |
| US 12,415,803 | Fused Imidazopyridines as Reversible Inhibitors of Brutons Tyrosine Kinase (BTK) In force · High confidence | In force | High confidence |
Also on record, not counted in the 4: 14 patents in force now held by others · 1 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.